Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 10/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423301 | 0.93 | LTA4H (0.48) | LTA4HESR1ESR2HTTMET | |
| SCHEMBL5429078 | 0.88 | LTA4H (0.50) | LTA4HESR1ESR2HTTKCNH2 | |
| SCHEMBL5431659 | 0.88 | LTA4H (0.51) | LTA4HESR1ESR2HTTKCNH2 | |
| SCHEMBL4930951 | 0.84 | ESR1 (0.50) | LTA4HESR1ESR2HTTMET | |
| SCHEMBL5706374 | 0.84 | SSTR2 (0.35) | LTA4H | |
| SCHEMBL5420872 | 0.82 | LTA4H (0.51) | LTA4HESR1ESR2KCNH2 | |
| SCHEMBL5426000 | 0.80 | LTA4H (0.47) | LTA4HESR1ESR2 | |
| SCHEMBL7110161 | 0.80 | ESR1 (0.53) | LTA4HESR1ESR2 | |
| SCHEMBL5826619 | 0.80 | LTA4H (0.49) | LTA4HESR1ESR2 | |
| SCHEMBL1359731 | 0.79 | ESR1 (0.60) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221163-A1 | Selective Estrogen Receptor Modulators | ELI LILLY AND COMPANY | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221163-A1 | Selective Estrogen Receptor Modulators | GPER1, ESR2, ESR1 | LTA4H 1500/4885ESR1 3/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.